SynthesisJAMA network open2020

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.

Peey-Sei Kok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.